Dr. Matthew Gevaert
CEO, KIYATEC, Inc.
Dr. Matthew (Matt) Gevaert is the Chief Executive Officer and a co-founder of KIYATEC, Inc. Under Matt’s leadership and with the support of an incredible team, KIYATEC has earned national recognition for its progress towards accurately modeling and predicting cancer patient response to drug therapies prior to treatment. Based on 3D cell culture technology, the company has pioneered a novel “in-hospital startup” model to solve intrinsically complex healthcare problems for the betterment of cancer patients, developing elegant solutions that will ultimately work both for the hospital “down the hall” as well as across the continent. Through a dedicated focus on direct relevance to cancer patients, KIYATEC has successfully attracted multiple rounds of private sector investment, more than $5M of competitively awarded federal funding including contracts from the National Cancer Institute, prestigious clinical collaborators at leading national cancer institutions and relationships with premier biopharmaceutical companies developing the cancer therapies of the future.
Matt is a graduate of the University of Waterloo (B.Sc., Chemistry) and of Clemson University (M.S. and Ph.D., Bioengineering). He serves on a number of professional and community boards and occasionally teaches an MBA graduate course in technology entrepreneurship for professional business students.